Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: A phase I-II randomized trial

Vaccine

Volumn 28, Issue 38, 2010, Pages 6221-6227

  Wu, Jiang ^a   Liu, Shu Zhen ^b   Dong, Shan Shan ^c   Dong, Xiao Ping ^d   Zhang, Wu Li ^d   Lu, Min ^a   Li, Chang Gui ^b   Zhou, Ji Chen ^d   Fang, Han Hua ^b   Liu, Yan ^c   Liu, Li Ying ^d   Qiu, Yuan Zheng ^c   Gao, Qiang ^c   Zhang, Xiao Mei ^c   Chen, Jiang Ting ^c   Zhong, Xiang ^c   Yin, Wei Dong ^c   Feng, Zi Jian ^d  

^a Beijing Centers for Diseases Control and Prevention   (China)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^c Sinovac Biotech Co Ltd   (China)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Children; H5N1; Influenza; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; AVIAN INFLUENZA VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANGINA PECTORIS; ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PANDEMIC INFLUENZA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; VACCINE PRODUCTION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE;

EID: 77955657329     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.008     Document Type: Article

References (21)

1. World Health Organization. DG Statement following the meeting of the Emergency Committee. (Accessed 5-08-2009). http://www.who.int/csr/disease/swineflu/4th_meeting_ihr/en/index.html.
2. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351:472-477.
3. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/ (H5N1) Reported to WHO. (Accessed 16-03-2010). http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_03_16/en/index.html.
4. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19:1732-1737.
5. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
6. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomized trial. Lancet 2006, 367:1657-1664.
7. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368:991-997.
8. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
9. Ehrlich H.J., Müller M., Oh H.M.L., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 Vaccine derived from cell culture. N Engl J Med 2008, 358:2573-2584.
10. Chotpitayasunondh T., Thisyakorn U., Pancharoen C., Pepin S., Nougarede N. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS One 2008, 3:e4028. 10.1371/journal.pone.0004028.
11. Nolan T., Richmond P.C., Formica N.T., Höschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008, 26:6383-6391.
12. Vajo Z., Kosa L., Szilvasy I., Pauliny Z., Bartha K., Visontay I., et al. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr Infect Dis J 2008, 27:1052-1056.
13. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M.D., et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005, 353:1374-1385.
14. Lin J.T., Li C.G., Wang X., Su N., Liu Y., Qiu Y.Z., et al. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J Infect Dis 2009, 199:184-187.
15. Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 2009, 48:1087-1095.
16. Nicolson C., Major D., Wood J.M., Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005, 23:2943-2952.
17. European Committee for Proprietary Medicinal Products Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03) 2004, European Agency for the Evaluation of Medicinal Products.
18. Division of Microbiology and Infectious Diseases. Pediatric toxicity table. (Accessed 16-03-2010). http://www3.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/toxtables.htm.
19. European Committee for Proprietary Medicinal Products Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96) 1997, European Agency for the Evaluation of Medicinal Products.
20. Meltzer M.I., Cox N.J., Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999, 5:659-671.
21. Glass L.M., Glass R.J. Social contact networks for the spread of pandemic influenza in children and teenagers. BMC Public Health 2008, 8:61.